Related Experiment Video
Updated: Jan 27, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
[Hepatitis B virus infection: control or cure?]
Marc Bourlière1, Valérie Oules1, Xavier Adhoute1
1Service d'hépatogastroentérologie, hôpital Saint-Joseph, 26, bd de Louvain, 13008 Marseille, France.
Insights
Hepatitis B virus (HBV) infection affects millions globally. Current treatments focus on controlling viral replication, but research aims for a cure by combining antiviral and immune therapies to achieve sustained HBsAg loss.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis B virus (HBV) infection is a significant global health concern with evolving epidemiology.
- Chronic HBV infection affects approximately 254 million people worldwide, with host immune response crucial to pathogenesis.
- Screening and vaccination are key public health strategies for managing HBV.
Purpose of the Study:
- To review the current landscape of Hepatitis B virus infection control and explore pathways toward a potential cure.
- To discuss the role of host immunity, screening, vaccination, and current treatment modalities.
- To highlight future research directions for achieving a functional cure for HBV.
Main Methods:
- Review of current literature on Hepatitis B virus infection epidemiology, pathogenesis, and treatment.
- Analysis of existing therapeutic strategies, including nucleos(t)ide analogues and pegylated interferon.
- Examination of research trends focusing on combination therapies and immune modulation.
Main Results:
- Current treatments aim for long-term viral suppression and biochemical response, with functional cure (HBsAg loss) as an optimal goal.
- Hepatitis B screening is recommended for individuals with risk factors or elevated ALT.
- Vaccination strategies are crucial for prevention in newborns and at-risk populations.
Conclusions:
- Achieving a cure for Hepatitis B virus infection requires a shift from viral suppression to immune restoration and complete viral clearance.
- Future research focuses on combination therapies targeting multiple stages of the HBV lifecycle and enhancing host immune responses.
- Developing treatments that lead to durable HBsAg loss and anti-HBs seroconversion remains the ultimate therapeutic objective.
Abstract:
Hepatitis b virus infection: control or cure? Hepatitis B virus infection remains a global public health issue with changing epidemiology due to several factors including vaccination policies and migration. Approximately 254 million individuals are chronic HBsAg carrier worldwide including around 300 000 individuals in France. Host immune response plays a key role in hepatitis B pathogenesis and clinical manifestations. Hepatitis B screening should be performed in all individual with risk factors and in patients with elevated ALT. Hepatitis B vaccination should be implemented at birth or during early childhood and in individuals with risk factors. The needs for curative treatment depend mainly on the stage of the disease. Current HBV treatment are based on long term use of nucleos(t)ide analogue and rarely on the use of finite duration of pegylated interferon. The endpoints of therapy are long-term suppression of HBV replication, biochemical response and optimally durable loss of HBsAg and anti-HBs seroconversion. Current and future research aim to develop combination with antiviral therapy targeting multiple steps in the HBV lifecycle that rapidly suppress viral replication and viral antigen production and immune modulatory therapy to restore immune response to HBV in order to achieve the goal of HBV cure.
More Related Videos
Related Concept Videos
Curing of Concrete
Curing Methods
Accelerated Curing of Concrete
What are Viruses?
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Portal System
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...

